Published in BMC Ophthalmol on April 11, 2015
Ranibizumab for neovascular age-related macular degeneration. N Engl J Med (2006) 30.63
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology (2012) 11.91
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology (2012) 8.29
Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med (2007) 6.47
Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology (2009) 6.44
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology (2012) 4.70
Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology (2013) 3.92
Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology (2008) 3.90
Seven new loci associated with age-related macular degeneration. Nat Genet (2013) 3.81
Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (spectralis). Am J Ophthalmol (2009) 3.47
Molecular pathology of age-related macular degeneration. Prog Retin Eye Res (2008) 3.35
Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology (2013) 2.82
Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol (2011) 2.49
The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology (2012) 2.30
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology (2007) 1.96
Comparison of retinal thickness in normal eyes using Stratus and Spectralis optical coherence tomography. Invest Ophthalmol Vis Sci (2009) 1.90
HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology (2012) 1.82
Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. Nat Genet (2013) 1.77
Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina (2009) 1.67
Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) (2007) 1.53
Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration. Acta Ophthalmol (2011) 1.24
Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study. Ophthalmology (2013) 1.11
A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmology (2013) 1.11
Sequence variants in HTRA1 and LOC387715/ARMS2 and phenotype and response to photodynamic therapy in neovascular age-related macular degeneration in populations from Israel. Mol Vis (2008) 1.10
Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment. Am J Ophthalmol (2012) 1.10
Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration. Ophthalmology (2012) 1.06
Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. Ophthalmology (2013) 1.00
CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration. J Ocul Biol Dis Infor (2010) 0.98
Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration. Br J Ophthalmol (2012) 0.91
The immunogenicity of disease-modifying therapies for multiple sclerosis: clinical implications for neurologists. Neurologist (2007) 0.89
Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population. Pharmacogenomics (2012) 0.86
Association of complement factor H Y402H polymorphism with phenotype of neovascular age related macular degeneration in Israel. Mol Vis (2008) 0.85
Pharmacogenetics of the treatment response of age-related macular degeneration with ranibizumab and bevacizumab. Semin Ophthalmol (2013) 0.82
Common variant in VEGFA and response to anti-VEGF therapy for neovascular age-related macular degeneration. Curr Mol Med (2013) 0.78